Paul R. Fonteyne - 06 Jan 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact for Paul Fonteyne
Issuer symbol
AMLX
Transactions as of
06 Jan 2022
Net transactions value
$0
Form type
3
Filing time
06 Jan 2022, 16:06:28 UTC
Previous filing
04 Jan 2022
Next filing
24 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AMLX Stock Option (Right to Buy) 06 Jan 2022 Common Stock 81,100 $6.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20,296 shares subject to such stock option shall vest on March 8, 2022 and the remainder of the shares vest in monthly installments of 1,689 shares thereafter.